DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
183.69
-0.08 (-0.04%)
At close: Aug 10, 2026, 4:00 PM EDT
183.50
-0.19 (-0.10%)
After-hours: Aug 10, 2026, 7:58 PM EDT
DaVita Revenue
DaVita had revenue of $3.55B in the quarter ending June 30, 2026, with 5.17% growth. This brings the company's revenue in the last twelve months to $14.01B, up 6.45% year-over-year. In the year 2025, DaVita had annual revenue of $13.64B with 6.46% growth.
Revenue (ttm)
$14.01B
Revenue Growth
+6.45%
P/S Ratio
0.84
Revenue / Employee
$179,611
Employees
78,000
Market Cap
11.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.64B | 827.52M | 6.46% |
| Dec 31, 2024 | 12.82B | 675.40M | 5.56% |
| Dec 31, 2023 | 12.14B | 530.25M | 4.57% |
| Dec 31, 2022 | 11.61B | -8.90M | -0.08% |
| Dec 31, 2021 | 11.62B | 68.19M | 0.59% |
| Dec 31, 2020 | 11.55B | 162.13M | 1.42% |
| Dec 31, 2019 | 11.39B | -16.37M | -0.14% |
| Dec 31, 2018 | 11.40B | 528.22M | 4.86% |
| Dec 31, 2017 | 10.88B | 169.17M | 1.58% |
| Dec 31, 2016 | 10.71B | 725.22M | 7.27% |
| Dec 31, 2015 | 9.98B | -2.81B | -21.98% |
| Dec 31, 2014 | 12.80B | 1.03B | 8.76% |
| Dec 31, 2013 | 11.76B | 3.58B | 43.70% |
| Dec 31, 2012 | 8.19B | 1.45B | 21.61% |
| Dec 31, 2011 | 6.73B | 512.20M | 8.24% |
| Dec 31, 2010 | 6.22B | 118.96M | 1.95% |
| Dec 31, 2009 | 6.10B | 440.48M | 7.78% |
| Dec 31, 2008 | 5.66B | 396.02M | 7.52% |
| Dec 31, 2007 | 5.26B | 383.49M | 7.86% |
| Dec 31, 2006 | 4.88B | 1.91B | 64.12% |
| Dec 31, 2005 | 2.97B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fresenius Medical Care AG | 22.19B |
| Tenet Healthcare | 21.81B |
| Universal Health Services | 18.11B |
| Encompass Health | 6.21B |
| Option Care Health | 5.69B |
| PACS Group | 5.55B |
| The Ensign Group | 5.49B |
| Chemed | 2.60B |
DVA News
- 3 days ago - DaVita price target lowered to $215 from $250 at Truist - TheFly
- 3 days ago - DaVita upgraded to Buy from Hold at TD Cowen - TheFly
- 5 days ago - DaVita price target raised to $265 from $220 at Deutsche Bank - TheFly
- 5 days ago - DaVita price target raised to $170 from $145 at BofA - TheFly
- 5 days ago - DaVita price target raised to $224 from $218 at Barclays - TheFly
- 6 days ago - DaVita flags lower revenue per treatment, reaffirms annual forecast - Reuters
- 6 days ago - DaVita Earnings Call Transcript: Q2 2026 - Transcripts
- 6 days ago - DaVita Earnings release: Q2 2026 - Filings